Enzyme-linked immunosorbent assay of 3 Screen Islet Cell Autoantibody in patients with autoimmune thyroid disease

Table 2 Prevalence of 3 Screen Islet Cell Autoantibody, autoantibodies to glutamic acid decarboxylase, insulinoma-associated antigen-2, and zinc transporter 8 in patients with autoimmune thyroid disease

	AITD with T1D		AITD with T2D		AITD without diabetes
	Graves, n = 5	Hashimoto, n = 13	Graves, n =40	Hashimoto, n = 41	Graves, n = 253	Hashimoto, n = 143
3 Screen ICA	5 (100.0)	11 (84.6)	4 (10.0)	1 (2.4)	14 (5.5)	6 (4.2)
GADA	4 (80.0)	10 (76.9)	3 (7.5)	1 (2.4)	11 (4.3)	5 (3.5)
IA-2A	1 (20.0)	3 (23.1)	1 (2.5)	0 (0.0)	1 (0.4)	0 (0.0)
ZnT8A	1 (20.0)	4 (30.8)	0 (0.0)	1 (2.4)	1 (0.4)	4 (2.8)
1Ab (+)	3 (60.0)	6 (46.2)	2 (5.0)	2 (4.9)	13 (5.1)	7 (4.9)
2Abs (+)	0 (0.0)	3 (23.1)	1 (2.5)	0 (0.0)	0 (0.0)	1 (0.7)
3Abs (+)	1 (20.0)	2 (15.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Data are n (%). Ab: Autoantibody; AITD: Autoimmune thyroid disease; T1D: Type 1 diabetes; T2D: Type 2 diabetes; 3 Screen ICA: 3 Screen Islet Cell Autoantibody; GADA: Glutamic acid decarboxylase 65 autoantibodies; IA-2A: Insulinoma-associated antigen-2 autoantibodies; ZnT8A: Zinc transporter 8 autoantibodies.